United Asset Strategies Inc. grew its position in Celgene Co. (NASDAQ:CELG) by 80.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,051 shares of the biopharmaceutical company’s stock after purchasing an additional 1,360 shares during the quarter. United Asset Strategies Inc.’s holdings in Celgene were worth $445,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Grisanti Capital Management LLC purchased a new stake in shares of Celgene during the second quarter valued at $3,616,000. RiverPoint Capital Management LLC grew its holdings in shares of Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after buying an additional 3,680 shares during the last quarter. Iguana Healthcare Management LLC grew its holdings in shares of Celgene by 12.5% during the first quarter. Iguana Healthcare Management LLC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $11,199,000 after buying an additional 10,000 shares during the last quarter. LSV Asset Management purchased a new stake in shares of Celgene during the second quarter valued at $1,701,000. Finally, Spectrum Management Group Inc. purchased a new stake in shares of Celgene during the second quarter valued at $462,000. 79.74% of the stock is currently owned by institutional investors and hedge funds.
Celgene Co. (CELG) opened at $106.68 on Friday. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market cap of $83,990.00, a PE ratio of 25.16, a P/E/G ratio of 0.69 and a beta of 1.77.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the firm earned $1.58 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. analysts forecast that Celgene Co. will post 6.68 earnings per share for the current year.
A number of equities research analysts have recently weighed in on the stock. Royal Bank of Canada reissued a “buy” rating and set a $147.00 price objective on shares of Celgene in a report on Thursday. SunTrust Banks set a $127.00 price objective on shares of Celgene and gave the company a “buy” rating in a report on Sunday, December 31st. Stifel Nicolaus dropped their price objective on shares of Celgene from $149.00 to $130.00 and set a “buy” rating on the stock in a report on Saturday, December 30th. Cantor Fitzgerald set a $112.00 price objective on shares of Celgene and gave the company a “hold” rating in a report on Friday, December 29th. Finally, Oppenheimer set a $166.00 price objective on shares of Celgene and gave the company a “buy” rating in a report on Thursday, December 28th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and twenty-one have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $132.59.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.